메뉴 건너뛰기




Volumn 7, Issue 5, 2007, Pages 727-737

Recent developments in renal cell cancer immunotherapy

Author keywords

Cytokines; Immunotherapy; Monoclonal antibodies; RCC; Therapeutic vaccines

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CD40 LIGAND MONOCLONAL ANTIBODY; CHEMOKINE RECEPTOR CXCR3; CPG OLIGODEOXYNUCLEOTIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; FLUOROURACIL; GAMMA INTERFERON; GP96 HEAT SHOCK PROTEIN VACCINE; HEAT SHOCK PROTEIN; INTERLEUKIN 2; IPILIMUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G250; ONCOPHAGE; RENCA H6 VACCINE; RENCA HEPATITIS B SURFACE ANTIGEN VACCINE; RITUXIMAB; SORAFENIB; TEMSIROLIMUS; THALIDOMIDE; TRASTUZUMAB; TUMOR CELL VACCINE; TUMOR VACCINE; UNCLASSIFIED DRUG;

EID: 34248200481     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.5.727     Document Type: Review
Times cited : (16)

References (97)
  • 1
    • 33750499711 scopus 로고    scopus 로고
    • LIPWORTH L TR, MCLAUGHLIN JK: The epidemiology of renal cell carcinoma. J. Urol. (2006) 176:2353-2358. Detailed and up-to-date information on RCC epidemiology.
    • LIPWORTH L TR, MCLAUGHLIN JK: The epidemiology of renal cell carcinoma. J. Urol. (2006) 176:2353-2358. Detailed and up-to-date information on RCC epidemiology.
  • 2
  • 3
    • 0003405565 scopus 로고    scopus 로고
    • SEER Cancer Sratistics Review, 1973-1999
    • Ries LA, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK Eds, National Cancer Institute, Bethesda, MD, USA
    • RIES LA, EISNER M, KOSARY CL et al.: SEER Cancer Sratistics Review, 1973-1999. In: SEER Cancer Statistics Review, 1973-1999. Ries LA, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK (Eds), National Cancer Institute, Bethesda, MD, USA (2002).
    • (2002) SEER Cancer Statistics Review, 1973-1999
    • RIES, L.A.1    EISNER, M.2    KOSARY, C.L.3
  • 4
    • 0036251451 scopus 로고    scopus 로고
    • Global increases in kidney cancer incidence, 1973-1992
    • MATHEW A, DEVESA SS, FRAUMENI JF JR, CHOW WH: Global increases in kidney cancer incidence, 1973-1992. Eur. J. Cancer Prev. (2002) 11(2):171-178.
    • (2002) Eur. J. Cancer Prev , vol.11 , Issue.2 , pp. 171-178
    • MATHEW, A.1    DEVESA, S.S.2    FRAUMENI JF JR, C.W.3
  • 5
    • 28844484134 scopus 로고    scopus 로고
    • Renal-cell carcinoma
    • COHEN HT, MCGOVERN FJ: Renal-cell carcinoma. N. Engl. J. Med. (2005) 353(23):2477-2490.
    • (2005) N. Engl. J. Med , vol.353 , Issue.23 , pp. 2477-2490
    • COHEN, H.T.1    MCGOVERN, F.J.2
  • 6
    • 84965188394 scopus 로고    scopus 로고
    • COPPIN C, PORZSOLT F, AWA A et al.: Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. (2005) (1):CD001425. This article summarizes results of all randomized clinical trials of immunotherapy in mRCC.
    • COPPIN C, PORZSOLT F, AWA A et al.: Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. (2005) (1):CD001425. This article summarizes results of all randomized clinical trials of immunotherapy in mRCC.
  • 7
    • 0036190056 scopus 로고    scopus 로고
    • Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: An experience of 405 cases
    • AMIN MB, AMIN MB, TAMBOLI P et al.: Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am. J. Surg. Pathol. (2002) 26(3):281-291.
    • (2002) Am. J. Surg. Pathol , vol.26 , Issue.3 , pp. 281-291
    • AMIN, M.B.1    AMIN, M.B.2    TAMBOLI, P.3
  • 8
    • 2142853538 scopus 로고    scopus 로고
    • Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma
    • BECK SD, PATEL MI, SNYDER ME et al.: Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann. Surg. Oncol. (2004) 11(1):71-77.
    • (2004) Ann. Surg. Oncol , vol.11 , Issue.1 , pp. 71-77
    • BECK, S.D.1    PATEL, M.I.2    SNYDER, M.E.3
  • 10
    • 33846148701 scopus 로고    scopus 로고
    • Sorafenib in advanced clear-cell renal-cell carcinoma
    • ESCUDIER B, EISEN T, STADLER WM et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. (2007) 356(2):125-134.
    • (2007) N. Engl. J. Med , vol.356 , Issue.2 , pp. 125-134
    • ESCUDIER, B.1    EISEN, T.2    STADLER, W.M.3
  • 11
    • 33846181370 scopus 로고    scopus 로고
    • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    • MOTZER RJ, HUTSON TE, TOMCZAK P et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. (2007) 356(2):115-124.
    • (2007) N. Engl. J. Med , vol.356 , Issue.2 , pp. 115-124
    • MOTZER, R.J.1    HUTSON, T.E.2    TOMCZAK, P.3
  • 13
    • 0019991789 scopus 로고
    • Spontaneous regression of metastatic renal cell carcinoma
    • SNOW RM, SCHELLHAMMER PF: Spontaneous regression of metastatic renal cell carcinoma. Urology (1982) 20(2):177-181.
    • (1982) Urology , vol.20 , Issue.2 , pp. 177-181
    • SNOW, R.M.1    SCHELLHAMMER, P.F.2
  • 14
    • 0017361999 scopus 로고
    • The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma
    • MONTIE JE, STEWART BH, STRAFFON RA et al.: The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J. Urol. (1977) 117(3):272-275.
    • (1977) J. Urol , vol.117 , Issue.3 , pp. 272-275
    • MONTIE, J.E.1    STEWART, B.H.2    STRAFFON, R.A.3
  • 15
    • 7144255510 scopus 로고    scopus 로고
    • Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group
    • GLEAVE ME, ELHILALI M, FRADET Y et al.: Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N. Engl. J. Med. (1998) 338(18):1265-1271.
    • (1998) N. Engl. J. Med , vol.338 , Issue.18 , pp. 1265-1271
    • GLEAVE, M.E.1    ELHILALI, M.2    FRADET, Y.3
  • 16
    • 0024539002 scopus 로고
    • Unexplained sponraneous regression and alpha-interferon as treatment for metastatic renal carcinoma
    • OLIVER RT, NETHERSELL AB, BOTTOMLEY JM: Unexplained sponraneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br. J. Urol. (1989) 63(2):128-131.
    • (1989) Br. J. Urol , vol.63 , Issue.2 , pp. 128-131
    • OLIVER, R.T.1    NETHERSELL, A.B.2    BOTTOMLEY, J.M.3
  • 17
    • 0035818877 scopus 로고    scopus 로고
    • Nephrecromy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
    • FLANIGAN RC, SALMON SE, BLUMENSTEIN BA et al.: Nephrecromy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl. J. Med. (2001) 345(23):1655- 1659.
    • (2001) N Engl. J. Med , vol.345 , Issue.23 , pp. 1655-1659
    • FLANIGAN, R.C.1    SALMON, S.E.2    BLUMENSTEIN, B.A.3
  • 18
    • 0035934596 scopus 로고    scopus 로고
    • Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial
    • MICKISCH GH, GARIN A, VAN POPPEL H, DE PRIJCK L, SYLVESTER R: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet (2001) 358(9286):966-970.
    • (2001) Lancet , vol.358 , Issue.9286 , pp. 966-970
    • MICKISCH, G.H.1    GARIN, A.2    VAN POPPEL, H.3    DE PRIJCK, L.4    SYLVESTER, R.5
  • 20
  • 21
    • 0141761508 scopus 로고    scopus 로고
    • Tumor escape from immune response: Mechanisms and targets of activity
    • GABRILOVICH D, PISAREV V: Tumor escape from immune response: mechanisms and targets of activity. Curr. Drug Targets (2003) 4(7):525-536.
    • (2003) Curr. Drug Targets , vol.4 , Issue.7 , pp. 525-536
    • GABRILOVICH, D.1    PISAREV, V.2
  • 22
    • 0036638978 scopus 로고    scopus 로고
    • Immunotherapy of metastatic renal cell cancer
    • FISHMAN M, SEIGNE J: Immunotherapy of metastatic renal cell cancer. Cancer Control (2002) 9(4):293-304.
    • (2002) Cancer Control , vol.9 , Issue.4 , pp. 293-304
    • FISHMAN, M.1    SEIGNE, J.2
  • 24
    • 0033514050 scopus 로고    scopus 로고
    • Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators
    • NO AUTHORS LISTED: Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet (1999) 353(9146):14-17.
    • (1999) Lancet , vol.353 , Issue.9146 , pp. 14-17
    • AUTHORS LISTED, N.1
  • 25
    • 0031804783 scopus 로고    scopus 로고
    • The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon
    • SMALL EJ, WEISS GR, MALIK UK et al.: The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon. Cancer J. Sci. Am. (1998) 4(3):162-167.
    • (1998) Cancer J. Sci. Am , vol.4 , Issue.3 , pp. 162-167
    • SMALL, E.J.1    WEISS, G.R.2    MALIK, U.K.3
  • 27
    • 0028266553 scopus 로고
    • Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2
    • ROSENBERG SA, YANG JC, TOPALIAN SL et al.: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA (1994) 271(12):907-913.
    • (1994) JAMA , vol.271 , Issue.12 , pp. 907-913
    • ROSENBERG, S.A.1    YANG, J.C.2    TOPALIAN, S.L.3
  • 28
    • 0032471712 scopus 로고    scopus 로고
    • Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response
    • ROSENBERG SA, YANG JC, WHITE DE, STEINBERG SM: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann. Surg. (1998) 228(3):307-319.
    • (1998) Ann. Surg , vol.228 , Issue.3 , pp. 307-319
    • ROSENBERG, S.A.1    YANG, J.C.2    WHITE, D.E.3    STEINBERG, S.M.4
  • 29
    • 16644401873 scopus 로고    scopus 로고
    • Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
    • MCDERMOTT DF, REGAN MM, CLARK JI et al.: Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. (2005) 23(1):133-141.
    • (2005) J. Clin. Oncol , vol.23 , Issue.1 , pp. 133-141
    • MCDERMOTT, D.F.1    REGAN, M.M.2    CLARK, J.I.3
  • 30
    • 0042914703 scopus 로고    scopus 로고
    • Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer
    • YANG JC, SHERRY RM, STEINBERG SM et al.: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. (2003) 21(16):3127-3132.
    • (2003) J. Clin. Oncol , vol.21 , Issue.16 , pp. 3127-3132
    • YANG, J.C.1    SHERRY, R.M.2    STEINBERG, S.M.3
  • 31
    • 33748686758 scopus 로고    scopus 로고
    • ReGel polymer-based delivery of interleukin-2 as a cancer treatment
    • SAMLOWSKI WE, MCGREGOR JR, JUREK M et al.: ReGel polymer-based delivery of interleukin-2 as a cancer treatment. J. Immunother. (2006) 29(5):524-535.
    • (2006) J. Immunother , vol.29 , Issue.5 , pp. 524-535
    • SAMLOWSKI, W.E.1    MCGREGOR, J.R.2    JUREK, M.3
  • 32
    • 0032528446 scopus 로고    scopus 로고
    • The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor
    • TANNENBAUM CS, TUBBS R, ARMSTRONG D et al.: The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J. Immunol. (1998) 161(2):927-932.
    • (1998) J. Immunol , vol.161 , Issue.2 , pp. 927-932
    • TANNENBAUM, C.S.1    TUBBS, R.2    ARMSTRONG, D.3
  • 33
    • 7444247430 scopus 로고    scopus 로고
    • CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease
    • MULLINS IM, SLINGLUFF CL, LEE JK et al.: CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res. (2004) 64(21):7697- 7701.
    • (2004) Cancer Res , vol.64 , Issue.21 , pp. 7697-7701
    • MULLINS, I.M.1    SLINGLUFF, C.L.2    LEE, J.K.3
  • 34
    • 0034192078 scopus 로고    scopus 로고
    • SHARMAS, STOLINA M, LOU J et al.: Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J. Immunol. (2000) 164(9):4558-4563.
    • SHARMAS, STOLINA M, LOU J et al.: Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J. Immunol. (2000) 164(9):4558-4563.
  • 35
    • 12744262853 scopus 로고    scopus 로고
    • CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibirion of vascular remodeling
    • BURDICK MD, MURRAY LA, KEANE MP et al.: CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibirion of vascular remodeling. Am. J. Respir. Crit. Care Med. (2005) 171(3):261-268.
    • (2005) Am. J. Respir. Crit. Care Med , vol.171 , Issue.3 , pp. 261-268
    • BURDICK, M.D.1    MURRAY, L.A.2    KEANE, M.P.3
  • 36
    • 3042855031 scopus 로고    scopus 로고
    • The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan
    • YANG J, RICHMOND A: The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol. Ther. (2004) 9(6):846-855.
    • (2004) Mol. Ther , vol.9 , Issue.6 , pp. 846-855
    • YANG, J.1    RICHMOND, A.2
  • 37
    • 31144468057 scopus 로고    scopus 로고
    • CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis
    • PAN J, BURDICK MD, BELPERIO JA et al.: CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J. Immunol. (2006) 176(3):1456-1464.
    • (2006) J. Immunol , vol.176 , Issue.3 , pp. 1456-1464
    • PAN, J.1    BURDICK, M.D.2    BELPERIO, J.A.3
  • 38
    • 33845594278 scopus 로고    scopus 로고
    • Sorafenib plus interferon-α2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG-412
    • GA, USA 2-6 June, Absrract
    • RYAN C, GOLDMAN B, LARA P et al.: Sorafenib plus interferon-α2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG-412. ASCO Annual Meeting. GA, USA (2-6 June 2006) Absrract 4525.
    • (2006) ASCO Annual Meeting , pp. 4525
    • RYAN, C.1    GOLDMAN, B.2    LARA, P.3
  • 39
    • 34248194715 scopus 로고    scopus 로고
    • Phase II trial of sorafenib plus inrerferon-alpha 2b (IFN-α2b) as first- or second-line therapy in parients with metastatic renal cell cancer
    • GA, USA 2, 6 June, Abstract 4538
    • GOLLOB JA, RICHMOND T, JONES J et al.: Phase II trial of sorafenib plus inrerferon-alpha 2b (IFN-α2b) as first- or second-line therapy in parients with metastatic renal cell cancer. ASCO Annual Meeting. GA, USA (2 - 6 June 2006) Abstract 4538.
    • (2006) ASCO Annual Meeting
    • GOLLOB, J.A.1    RICHMOND, T.2    JONES, J.3
  • 40
    • 33748363166 scopus 로고    scopus 로고
    • A Phase III, randomized, 3-arm srudy of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatement of first-line, poor-risk patients with advanced renall cell carcinoma
    • GA, USA 2-6 June, Absrract
    • HUDES G, CARDUCCI M, TOMCZAK P et al.: A Phase III, randomized, 3-arm srudy of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatement of first-line, poor-risk patients with advanced renall cell carcinoma. ASCO Annual Meeting. GA, USA (2-6 June 2006) Absrract LBA4.
    • (2006) ASCO Annual Meeting
    • HUDES, G.1    CARDUCCI, M.2    TOMCZAK, P.3
  • 41
    • 33645816541 scopus 로고    scopus 로고
    • Phase I/II study of thalidomide in combination with interleukin-2
    • patients with metastatic renal cell carcinoma, :1498-15()6
    • AMATO RJ, MORGAN M, RAWAT A: Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma. Cancer (2006) 106(7):1498-15()6.
    • (2006) Cancer , vol.106 , Issue.7
    • AMATO, R.J.1    MORGAN, M.2    RAWAT, A.3
  • 42
    • 16844365788 scopus 로고    scopus 로고
    • Narurally arising Foxp3-expressing CD25+CD4+ regularory T cells in immunological tolerance to self and non-self
    • SAKAGUCHI S: Narurally arising Foxp3-expressing CD25+CD4+ regularory T cells in immunological tolerance to self and non-self. Nat. Immunol. (2005) 6(4):345-352.
    • (2005) Nat. Immunol , vol.6 , Issue.4 , pp. 345-352
    • SAKAGUCHI, S.1
  • 43
    • 16844362608 scopus 로고    scopus 로고
    • VON BOEHMER H: Mechanisms of suppression by suppressor T cells. Nat. Immunol. (2005) 6(4):338-344. This article clearly depicts the role and function of suppressor T cells.
    • VON BOEHMER H: Mechanisms of suppression by suppressor T cells. Nat. Immunol. (2005) 6(4):338-344. This article clearly depicts the role and function of suppressor T cells.
  • 44
    • 33644784733 scopus 로고    scopus 로고
    • AHMADZADEH M, ROSENBERG SA: IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood (2006) 107(6):2409-2414. This article sheds a new light on the modest clinical efficacy of IL-2 in cancer patients.
    • AHMADZADEH M, ROSENBERG SA: IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood (2006) 107(6):2409-2414. This article sheds a new light on the modest clinical efficacy of IL-2 in cancer patients.
  • 45
    • 34248201884 scopus 로고    scopus 로고
    • Treg depletion with denileukin difititox (DD) enhances lymphocytosis and eosinophilia in patients treated with high-dose IL-2 (HDIL-2) for metastatic renal cell Cancer (MRCC)
    • GA, USA 2-6 June, Abstract 14627
    • GIDRON A, EKLUND J, MORTONE B et al.: Treg depletion with denileukin difititox (DD) enhances lymphocytosis and eosinophilia in patients treated with high-dose IL-2 (HDIL-2) for metastatic renal cell Cancer (MRCC). ASCO Annual Meeting. GA, USA (2-6 June 2006) Abstract 14627.
    • (2006) ASCO Annual Meeting
    • GIDRON, A.1    EKLUND, J.2    MORTONE, B.3
  • 46
    • 33749424944 scopus 로고    scopus 로고
    • Vaccines in renal cell carcinoma
    • KUBLER H, VIEWEG J: Vaccines in renal cell carcinoma. Semin. Oncol. (2006) 33(5):614-624.
    • (2006) Semin. Oncol , vol.33 , Issue.5 , pp. 614-624
    • KUBLER, H.1    VIEWEG, J.2
  • 47
    • 9144238981 scopus 로고    scopus 로고
    • Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma
    • DILLMAN R, BARTH N, VANDERMOLEN L et al.. Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma. Cancer Biother. Radiopharm. (2004) 19(5):570-580.
    • (2004) Cancer Biother. Radiopharm , vol.19 , Issue.5 , pp. 570-580
    • DILLMAN, R.1    BARTH, N.2    VANDERMOLEN, L.3
  • 48
    • 0025642936 scopus 로고
    • Renal cell carcinoma treated by vaccines for active specific immunotherapy: Correlation of survival with skin testing by autologous tumor cells
    • MCCUNE CS, O'DONNELL RW, MARQUIS DM, SAHASRABUDHE DM: Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol. Immunother. (1990) 32(1):62-66.
    • (1990) Cancer Immunol. Immunother , vol.32 , Issue.1 , pp. 62-66
    • MCCUNE, C.S.1    O'DONNELL, R.W.2    MARQUIS, D.M.3    SAHASRABUDHE, D.M.4
  • 49
    • 0034068534 scopus 로고    scopus 로고
    • A randomized Phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: Clinical outcome and analysis of immunological parameters
    • SCHWAAB T, HEANEY JA, SCHNED AR et al.: A randomized Phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters. J. Urol. (2000) 163(4):1322-1327.
    • (2000) J. Urol , vol.163 , Issue.4 , pp. 1322-1327
    • SCHWAAB, T.1    HEANEY, J.A.2    SCHNED, A.R.3
  • 50
    • 12144288442 scopus 로고    scopus 로고
    • Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma
    • SCHWAAB T, TRETTER CP, GIBSON JJ et al.: Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma. J. Urol. (2004) 171(3):1036- 1042.
    • (2004) J. Urol , vol.171 , Issue.3 , pp. 1036-1042
    • SCHWAAB, T.1    TRETTER, C.P.2    GIBSON, J.J.3
  • 51
    • 0036223749 scopus 로고    scopus 로고
    • Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma
    • ANTONIA SJ, SEIGNE J, DIAZ J et al.: Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J. Urol. (2002) 167(5):1995-2000.
    • (2002) J. Urol , vol.167 , Issue.5 , pp. 1995-2000
    • ANTONIA, S.J.1    SEIGNE, J.2    DIAZ, J.3
  • 52
    • 20844460949 scopus 로고    scopus 로고
    • Allogeneic gene-modified tumour cells in metastatic kidney cancer. Report II
    • PIZZA G, DE VINCI C, LO CONTE G et al.: Allogeneic gene-modified tumour cells in metastatic kidney cancer. Report II. Folia Biol. (Praha) (2004) 50(6):175-183.
    • (2004) Folia Biol. (Praha) , vol.50 , Issue.6 , pp. 175-183
    • PIZZA, G.1    DE VINCI, C.2    LO CONTE, G.3
  • 53
    • 0030944023 scopus 로고    scopus 로고
    • Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer
    • SIMONS JW, JAFFEE EM, WEBER CE et al.: Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. (1997) 57(8):1537-1546.
    • (1997) Cancer Res , vol.57 , Issue.8 , pp. 1537-1546
    • SIMONS, J.W.1    JAFFEE, E.M.2    WEBER, C.E.3
  • 54
    • 4644299284 scopus 로고    scopus 로고
    • Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: Clinical and immunological findings
    • TANI K, AZUMA M, NAKAZAKI Y et al.. Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings. Mol. Ther. (2004) 10(4):799-816.
    • (2004) Mol. Ther , vol.10 , Issue.4 , pp. 799-816
    • TANI, K.1    AZUMA, M.2    NAKAZAKI, Y.3
  • 55
    • 30144444279 scopus 로고    scopus 로고
    • Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells
    • DANNULL J, SU Z, RIZZIERI D et al.: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. (2005) 115(12):3623-3633.
    • (2005) J. Clin. Invest , vol.115 , Issue.12 , pp. 3623-3633
    • DANNULL, J.1    SU, Z.2    RIZZIERI, D.3
  • 56
    • 0038066552 scopus 로고    scopus 로고
    • Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells
    • SU Z, DANNULL J, HEISER A et al.: Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. (2003) 63(9):2127- 2133.
    • (2003) Cancer Res , vol.63 , Issue.9 , pp. 2127-2133
    • SU, Z.1    DANNULL, J.2    HEISER, A.3
  • 57
    • 10744232378 scopus 로고    scopus 로고
    • GITLITZ BJ, BELLDEGRUN AS, ZISMAN A et al.: A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J. Immunother. (2003) 26(5):412-419.
    • GITLITZ BJ, BELLDEGRUN AS, ZISMAN A et al.: A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J. Immunother. (2003) 26(5):412-419.
  • 58
    • 0036845714 scopus 로고    scopus 로고
    • Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells
    • HOLTL L, ZELLE-RIESER C, GANDER H et al.: Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin. Cancer Res. (2002) 8(11):3369-3376.
    • (2002) Clin. Cancer Res , vol.8 , Issue.11 , pp. 3369-3376
    • HOLTL, L.1    ZELLE-RIESER, C.2    GANDER, H.3
  • 59
    • 19244365218 scopus 로고    scopus 로고
    • Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: A Phase I study
    • OOSTERWIJK-WAKKA JC, TIEMESSEN DM, BLEUMER I et al.: Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a Phase I study. J. Immunother. (2002) 25(6):500-508.
    • (2002) J. Immunother , vol.25 , Issue.6 , pp. 500-508
    • OOSTERWIJK-WAKKA, J.C.1    TIEMESSEN, D.M.2    BLEUMER, I.3
  • 60
    • 3242666031 scopus 로고    scopus 로고
    • Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses
    • AVIGAN D, VASIR B, GONG J et al.: Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res. (2004) 10(14):4699-4708.
    • (2004) Clin. Cancer Res , vol.10 , Issue.14 , pp. 4699-4708
    • AVIGAN, D.1    VASIR, B.2    GONG, J.3
  • 61
    • 4043156133 scopus 로고    scopus 로고
    • Dendritic cell-tumor cell hybrid vaccination for metastatic cancer
    • BARBUTO JA, ENSINA LF, NEVES AR et al.: Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunol. Immunother. (2004) 53(12):1111-1118.
    • (2004) Cancer Immunol. Immunother , vol.53 , Issue.12 , pp. 1111-1118
    • BARBUTO, J.A.1    ENSINA, L.F.2    NEVES, A.R.3
  • 62
    • 0037457018 scopus 로고    scopus 로고
    • Allogeneic dendritic cells fused with tumor cells: Preclinical results and outcome of a clinical Phase I/II trial in patients with metastatic renal cell carcinoma
    • MARTEN A, RENOTH S, HEINICKE T et al.: Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical Phase I/II trial in patients with metastatic renal cell carcinoma. Hum. Gene Ther. (2003) 14(5):483-494.
    • (2003) Hum. Gene Ther , vol.14 , Issue.5 , pp. 483-494
    • MARTEN, A.1    RENOTH, S.2    HEINICKE, T.3
  • 63
    • 33746374452 scopus 로고    scopus 로고
    • Protective effect of irradiated renal carcinoma expressing hepatitis B surface antigen against renal-cell carcinoma-mediated tumors
    • MOON Y, CHO SG, LEE JW et al.: Protective effect of irradiated renal carcinoma expressing hepatitis B surface antigen against renal-cell carcinoma-mediated tumors. Cancer Biother. Radiopharm. (2006) 21(3):211-216.
    • (2006) Cancer Biother. Radiopharm , vol.21 , Issue.3 , pp. 211-216
    • MOON, Y.1    CHO, S.G.2    LEE, J.W.3
  • 64
    • 10744230275 scopus 로고    scopus 로고
    • JOCHAM D, RICHTER A, HOFFMANN L et al.: Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrecromy: Phase III, randomised controlled trial. Lancet (2004) 363(9409):594-599. The first trial demonstrating the efficacy of immunotherapy (autologous vaccine) in an adjuvant setting in RCC patients.
    • JOCHAM D, RICHTER A, HOFFMANN L et al.: Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrecromy: Phase III, randomised controlled trial. Lancet (2004) 363(9409):594-599. The first trial demonstrating the efficacy of immunotherapy (autologous vaccine) in an adjuvant setting in RCC patients.
  • 65
    • 19944429320 scopus 로고    scopus 로고
    • Phase I/II trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors: Miscellaneous tumors
    • MOISEYENKO VM, DANILOV AO, BALDUEVA IA et al.: Phase I/II trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors: miscellaneous tumors. Ann. Oncol. (2005) 16(1):162-168.
    • (2005) Ann. Oncol , vol.16 , Issue.1 , pp. 162-168
    • MOISEYENKO, V.M.1    DANILOV, A.O.2    BALDUEVA, I.A.3
  • 67
    • 1642456671 scopus 로고    scopus 로고
    • Dendritic cells: Immunobiology and cancer immunotherapy
    • ARDAVIN C, AMIGORENA S, REIS E SOUSA C: Dendritic cells: immunobiology and cancer immunotherapy. Immunity (2004) 20(1):17-23.
    • (2004) Immunity , vol.20 , Issue.1 , pp. 17-23
    • ARDAVIN, C.1    AMIGORENA, S.2    REIS, E.3    SOUSA, C.4
  • 69
    • 0032546352 scopus 로고    scopus 로고
    • Dendritic cells and the control of immunity
    • BANCHEREAU J, STEINMAN RM: Dendritic cells and the control of immunity. Nature (1998) 392(6673):245-252.
    • (1998) Nature , vol.392 , Issue.6673 , pp. 245-252
    • BANCHEREAU, J.1    STEINMAN, R.M.2
  • 70
    • 0035139983 scopus 로고    scopus 로고
    • Danger signals: SOS to the immune system
    • GALLUCCI S, MATZINGER P: Danger signals: SOS to the immune system. Curr. Opin. Immunol. (2001) 13(1):114-119.
    • (2001) Curr. Opin. Immunol , vol.13 , Issue.1 , pp. 114-119
    • GALLUCCI, S.1    MATZINGER, P.2
  • 71
    • 3042628507 scopus 로고    scopus 로고
    • CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice
    • SWITAJ T, JALILI A, JAKUBOWSKA AB et al.: CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice. Clin. Cancer Res. (2004) 10(12 Pt 1):4165-4175.
    • (2004) Clin. Cancer Res , vol.10 , Issue.12 PART 1 , pp. 4165-4175
    • SWITAJ, T.1    JALILI, A.2    JAKUBOWSKA, A.B.3
  • 72
    • 12944255776 scopus 로고    scopus 로고
    • CHAGNON F, TANGUAY S, OZDAL OL et al.: Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides. Clin. Cancer Res. (2005) 11(3):1302-1311.
    • CHAGNON F, TANGUAY S, OZDAL OL et al.: Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides. Clin. Cancer Res. (2005) 11(3):1302-1311.
  • 73
    • 34248139399 scopus 로고    scopus 로고
    • Treatment of advanced renal cell carcinoma with tumor lysate pulsed IL-12 secreting autologous dendritic cells
    • GA, USA 2-6 June, Abstract 14585
    • WIMPISSINGER T, FELZMANN T, HUGEL H, FUNOVICS P, STACKL W: Treatment of advanced renal cell carcinoma with tumor lysate pulsed IL-12 secreting autologous dendritic cells. ASCO Annual Meeting. GA, USA (2-6 June 2006) Abstract 14585.
    • (2006) ASCO Annual Meeting
    • WIMPISSINGER, T.1    FELZMANN, T.2    HUGEL, H.3    FUNOVICS, P.4    STACKL, W.5
  • 74
    • 33745247366 scopus 로고    scopus 로고
    • Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients
    • WIERECKY J, MULLER MR, WIRTHS S et al.: Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. (2006) 66(11):5910-5918.
    • (2006) Cancer Res , vol.66 , Issue.11 , pp. 5910-5918
    • WIERECKY, J.1    MULLER, M.R.2    WIRTHS, S.3
  • 75
    • 0347100681 scopus 로고    scopus 로고
    • Phase II study of autologous tumor derived heat shock protein-peptide complex vaccine (HSPPC-96) for patients with metastatic renal cell carcinoma
    • ASSIKI V, DALIANI D, PAGLIARO L et al.: Phase II study of autologous tumor derived heat shock protein-peptide complex vaccine (HSPPC-96) for patients with metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. (2003) 22:386.
    • (2003) Proc. Am. Soc. Clin. Oncol , vol.22 , pp. 386
    • ASSIKI, V.1    DALIANI, D.2    PAGLIARO, L.3
  • 76
    • 11144354471 scopus 로고    scopus 로고
    • A Phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients
    • BLEUMER I, KNUTH A, OOSTERWIJK E et al.: A Phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br. J. Cancer (2004) 90(5):985-990.
    • (2004) Br. J. Cancer , vol.90 , Issue.5 , pp. 985-990
    • BLEUMER, I.1    KNUTH, A.2    OOSTERWIJK, E.3
  • 77
    • 33646862241 scopus 로고    scopus 로고
    • Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression
    • SHORTS L, WEISS JM, LEE JK et al.: Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression. J. Immunol. (2006) 176(11):6543-6552.
    • (2006) J. Immunol , vol.176 , Issue.11 , pp. 6543-6552
    • SHORTS, L.1    WEISS, J.M.2    LEE, J.K.3
  • 78
    • 28844487782 scopus 로고    scopus 로고
    • Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010)
    • Orlando, FL, USA 13-17 May, Abstract 2501
    • YANG J, BECK K, BLANSFIELD J et al.: Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010). ASCO Annual Meeting. Orlando, FL, USA (13-17 May 2005). Abstract 2501.
    • (2005) ASCO Annual Meeting
    • YANG, J.1    BECK, K.2    BLANSFIELD, J.3
  • 79
    • 33744792341 scopus 로고    scopus 로고
    • Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
    • BECK KE, BLANSFIELD JA, TRAN KQ et al.: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. (2006) 24(15):2283-2289.
    • (2006) J. Clin. Oncol , vol.24 , Issue.15 , pp. 2283-2289
    • BECK, K.E.1    BLANSFIELD, J.A.2    TRAN, K.Q.3
  • 80
    • 0027529476 scopus 로고
    • Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer
    • ROSENBERG SA, LOTZE MT, YANG JC et al.: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl Cancer Inst. (1993) 85(8):622-632.
    • (1993) J. Natl Cancer Inst , vol.85 , Issue.8 , pp. 622-632
    • ROSENBERG, S.A.1    LOTZE, M.T.2    YANG, J.C.3
  • 81
    • 34247260551 scopus 로고    scopus 로고
    • Immunotherapy for renal cell cancer
    • YANG JC, CHILDS R: Immunotherapy for renal cell cancer. J. Clin. Oncol. (2006) 24(35):5576-5583.
    • (2006) J. Clin. Oncol , vol.24 , Issue.35 , pp. 5576-5583
    • YANG, J.C.1    CHILDS, R.2
  • 83
    • 33846813974 scopus 로고    scopus 로고
    • Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: A pilot study
    • KOBAYASHI H, TANAKA Y, YAGI J et al.: Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother. (2006) 56(4):469-476.
    • (2006) Cancer Immunol Immunother , vol.56 , Issue.4 , pp. 469-476
    • KOBAYASHI, H.1    TANAKA, Y.2    YAGI, J.3
  • 84
    • 0036019378 scopus 로고    scopus 로고
    • Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer
    • LAMERS CH, WILLEMSEN RA, LUIDER BA, DEBETS R, BOLHUIS RL: Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer. Cancer Gene Ther. (2002) 9(7):613-623.
    • (2002) Cancer Gene Ther , vol.9 , Issue.7 , pp. 613-623
    • LAMERS, C.H.1    WILLEMSEN, R.A.2    LUIDER, B.A.3    DEBETS, R.4    BOLHUIS, R.L.5
  • 85
    • 33646440024 scopus 로고    scopus 로고
    • Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience
    • LAMERS CH, SLEIJFER S, VULTO AG et al.: Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. (2006) 24(13):e20-e22.
    • (2006) J. Clin. Oncol , vol.24 , Issue.13
    • LAMERS, C.H.1    SLEIJFER, S.2    VULTO, A.G.3
  • 86
    • 0032607572 scopus 로고    scopus 로고
    • Historical markers in the development of allogeneic hematopoietic cell transplantation
    • THOMAS ED, BLUME KG: Historical markers in the development of allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. (1999) 5(6):341-346.
    • (1999) Biol. Blood Marrow Transplant , vol.5 , Issue.6 , pp. 341-346
    • THOMAS, E.D.1    BLUME, K.G.2
  • 87
    • 0025678601 scopus 로고
    • Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
    • KOLB HJ, MITTERMULLER J, CLEMM C et al.: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood (1990) 76(12):2462-2465.
    • (1990) Blood , vol.76 , Issue.12 , pp. 2462-2465
    • KOLB, H.J.1    MITTERMULLER, J.2    CLEMM, C.3
  • 88
    • 33745588857 scopus 로고    scopus 로고
    • BARKHOLT L, BREGNI M, REMBERGER M et al.: Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann. Oncol. (2006) 17(7):1134-1140. This article reports the largest experience to date of allogeneic HSCT for mRCC.
    • BARKHOLT L, BREGNI M, REMBERGER M et al.: Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann. Oncol. (2006) 17(7):1134-1140. This article reports the largest experience to date of allogeneic HSCT for mRCC.
  • 89
    • 20144384975 scopus 로고    scopus 로고
    • Allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of metastatic renal cell carcinoma - single center experience
    • RZEPECKI P, ZOLNIEREK J, SAROSIEK T, LANGIEWICZ P, SZCZYLIK C: Allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of metastatic renal cell carcinoma - single center experience. Neoplasma (2005) 52(3):238-242.
    • (2005) Neoplasma , vol.52 , Issue.3 , pp. 238-242
    • RZEPECKI, P.1    ZOLNIEREK, J.2    SAROSIEK, T.3    LANGIEWICZ, P.4    SZCZYLIK, C.5
  • 90
    • 8744315211 scopus 로고    scopus 로고
    • Antigenic targets for renal cell carcinoma immunotherapy
    • VIEWEG J, JACKSON A: Antigenic targets for renal cell carcinoma immunotherapy. Expert Opin. Biol. Ther. (2004) 4(11):1791-1801.
    • (2004) Expert Opin. Biol. Ther , vol.4 , Issue.11 , pp. 1791-1801
    • VIEWEG, J.1    JACKSON, A.2
  • 92
    • 33746074464 scopus 로고    scopus 로고
    • Captopril, an angiotensin-converting enzyme inhibitor, promotes growth of immunogenic tumors in mice
    • WYSOCKI PJ, KWIATKOWSKA EP, KAZIMIERCZAK U et al.: Captopril, an angiotensin-converting enzyme inhibitor, promotes growth of immunogenic tumors in mice. Clin. Cancer Res. (2006) 12(13):4095-4102.
    • (2006) Clin. Cancer Res , vol.12 , Issue.13 , pp. 4095-4102
    • WYSOCKI, P.J.1    KWIATKOWSKA, E.P.2    KAZIMIERCZAK, U.3
  • 93
    • 33646357786 scopus 로고    scopus 로고
    • MICHAELIS LC, RATAIN MJ: Measuring response in a post-RECIST world: from black and white to shades of grey. Nat. Rev. Cancer (2006) 6(5):409-414. This article summarizes the drawbacks of the existing tumor response evaluation criteria (RECIST) if used for non-chemotherapy-based clinical trials.
    • MICHAELIS LC, RATAIN MJ: Measuring response in a post-RECIST world: from black and white to shades of grey. Nat. Rev. Cancer (2006) 6(5):409-414. This article summarizes the drawbacks of the existing tumor response evaluation criteria (RECIST) if used for non-chemotherapy-based clinical trials.
  • 94
    • 23844469804 scopus 로고    scopus 로고
    • Phase II oncology trials: Let's be positive
    • RATAIN MJ: Phase II oncology trials: let's be positive. Clin. Cancer Res. (2005) 11(16):5661-5662.
    • (2005) Clin. Cancer Res , vol.11 , Issue.16 , pp. 5661-5662
    • RATAIN, M.J.1
  • 95
    • 16544380415 scopus 로고    scopus 로고
    • Phase II srudies of modern drugs directed against new targets: If you are fazed, too, then resist RECIST
    • RATAIN MJ, ECKHARDT SG: Phase II srudies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J. Clin. Oncol. (2004) 22(22):4442-4445.
    • (2004) J. Clin. Oncol , vol.22 , Issue.22 , pp. 4442-4445
    • RATAIN, M.J.1    ECKHARDT, S.G.2
  • 96
    • 11144251200 scopus 로고    scopus 로고
    • Cancer vaccines: Pessimism in check
    • 1278-1279; author reply 1279-1280
    • MOCELLIN S, MANDRUZZATO S, BRONTE V, MARINCOLA FM: Cancer vaccines: pessimism in check. Nat. Med. (2004) 10(12):1278-1279; author reply 1279-1280.
    • (2004) Nat. Med , vol.10 , Issue.12
    • MOCELLIN, S.1    MANDRUZZATO, S.2    BRONTE, V.3    MARINCOLA, F.M.4
  • 97
    • 33744954585 scopus 로고    scopus 로고
    • Sunitinib in patients with metastatic renal cell carcinoma
    • MOTZER RJ, RINI BI, BUKOWSKI RM et al.: Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 295(21):2516-2524.
    • (2006) JAMA , vol.295 , Issue.21 , pp. 2516-2524
    • MOTZER, R.J.1    RINI, B.I.2    BUKOWSKI, R.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.